Brief: Cantargia Granted Important Us Patent For Nadunolimab

Cantargia AB

27/08/2025 06:32

Aug 27 (Reuters) - Cantargia AB CANTA.ST:

GRANTED IMPORTANT US PATENT FOR NADUNOLIMAB

PATENT IS VALID UNTIL 2035 (EXCLUDING ANY PATENT TERM EXTENSION)

Source text: ID:nMFN5xrqDl

Further company coverage: CANTA.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))